Findings published in Oncotarget offer new hope for children with highly aggressive brain tumors like atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma. Previously, the authors of the study have shown that an experimental drug that inhibits polo-like kinase 4 (PLK4) stopped pediatric brain tumor growth in vitro. Now, they have demonstrated its success in an animal model – the drug…
Neagen and Visiopharm announce an integration which improves the data quality of cancer patient samples in a single PACS-driven digital pathology workflow also offering time and cost savings. This in term enhances quality for pathologists working in cancer research and diagnostics and benefits the patients.
Every cancer is different and every patient is different. This insight gained in personalised medicine prompted oncology researchers to focus more on the individual patient’s immune system. It is particularly the immune system’s ability to destroy cancer cells that raised hope.
Unlike the USA, Italy, Germany or the Netherlands, Spain does not include hyperthermia in its national health catalogue. Worse, many non-medical centres are increasingly offering hyperthermia as an alternative treatment, a situation that infuriates Spanish oncologic radiotherapists.
The UC Davis Comparative Oncology Program joins oncologists at both the vet school and cancer center to test novel treatments on companion dogs with spontaneous tumors that could be effective in human patients with cancer. Human clinical trials could be started this year.
Language recognition on the smartphone, spam filters in the e-mail programme, personalised product recommendations by Amazon or Netflix – all share one feature: they are based on an algorithm that recognises patterns in a set of data. This artificial generation of knowledge is called machine learning.
Inhibition of the enzyme RIOK1 could stop the growth of tumors and the development of metastases
Even in remission, cancer looms. Former cancer patients and their doctors are always on alert for metastatic tumors. Now scientists at The Scripps Research Institute (TSRI) have discovered why some cancers may reoccur after years in remission.
Although radiation therapy is an essential part of modern cancer treatment, and is indicated for about half of all new cancer patients, facilities for its provision are sadly lacking in many countries worldwide. Indeed, 29 out of 52 African nations have no radiotherapy facilities whatsoever. At the ESTRO 36 conference leaders of the European Society for Radiotherapy and Oncology (ESTRO) will…
Paxman Coolers Limited announced today that The U.S. Food and Drug Administration (FDA) has cleared the company to market the Paxman Scalp Cooling System, a scalp cooling technology that was developed by a British family to reduce hair loss (alopecia) in breast cancer patients undergoing chemotherapy.
Pentax Medical EMEA announces its continued cooperation with SMART Medical to support the distribution and deployment of SMART’s G-EYE technology integrated with Pentax Medical’s HD+ systems to the EMEA market.
The new Sofia 3-D breast ultrasound system solves all the economic and logistic challenges associated with whole-breast ultrasound by using a full-field radial scanning method, the firm reports. The resulting throughput, efficiency, and patient comfort make Sofia an ideal solution for women with dense breasts.
Columbia University Medical Center (CUMC) researchers have created a computational tool that can rapidly predict which genes are implicated in an individual’s cancer and recommend treatments. It is among the most comprehensive tools of its kind, and the first that incorporates a user-friendly web interface that requires little knowledge of bioinformatics.
A combination of a diabetes medication and an antihypertensive drug can effectively combat cancer cells. The team of researchers led by Prof. Michael Hall at the Biozentrum of the University of Basel has also reported that specific cancer cells respond to this combination of drugs.
Researchers at University of Vienna discover unexpected role of signalling protein in hepatocellular carcinoma.
A team of UCLA bioengineers has demonstrated that its technology may go a long way toward overcoming the challenges of treatment for acute lymphoblastic leukemia, among the most common types of cancer in children, and has the potential to help doctors personalize drug doses.
University of Adelaide researchers have developed an optical fiber probe that distinguishes breast cancer tissue from normal tissue – potentially allowing surgeons to be much more precise when removing breast cancer.
When Kerstin Stenson, MD, describes the innovative technique she is helping develop to fight cancer, it seems like she’s describing a Tom Clancy military espionage novel.
Physicians have long used visual judgment of medical images to determine the course of cancer treatment. A new program package from Fraunhofer researchers reveals changes in images and facilitates this task using deep learning. The experts will demonstrate this software in Chicago from November 27 to December 2 at RSNA, the world’s largest radiology meeting.
At the MEDICA 2016 IMMS is presenting its first approaches for the personalized diagnostics of cancer using a prototype device. It was developed in the three-year research project INSPECT which started in June 2016.
Brain cancer treatment is taking a major step ahead as Spanish surgeons pioneer a new technique that spares language and motion functions. This splendid development might even one day result in epilepsy surgery.
Scientists have shown that a mutation in a gene called Arid1b can cause liver cancer. The gene normally protects against cancer by limiting cell growth, but when mutated it allows cells to grow uncontrollably. The researchers have shown that two existing drugs can halt this growth in human cells. This points to a new approach to treating liver cancer.
How to cut the high cost of cancer drugs engendered high interest at the recent Forum on Hospital Management held in Vienna.
Bladder cancer (BC) is the most common malignancy involving the urinary system and the ninth most common malignancy worldwide.
‘Today Vienna is one of the top addresses with regard to breast cancer research,’ Professor Michael Gnant proudly reports – and he certainly knows what he is talking about.